Lewy body Dementia - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 34

Lewy body Dementia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Lewy body Dementia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lewy body Dementia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lewy body Dementia. Lewy body Dementia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lewy body Dementia.
- A review of the Lewy body Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lewy body Dementia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lewy body Dementia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lewy body Dementia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Lewy body Dementia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Lewy body Dementia 7
Lewy body Dementia Therapeutics under Development by Companies 9
Lewy body Dementia Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Lewy body Dementia Therapeutics – Products under Development by Companies 14
Lewy body Dementia Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Lewy body Dementia Therapeutics Development 16
Eisai Co., Ltd. 16
BioArctic Neuroscience AB 17
Varinel, Inc. 18
Lewy body Dementia – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
donepezil hydrochloride - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
VAR-10100 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
memantine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PD-0805 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Alpha-Synuclein Antibody - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Lewy body Dementia Therapeutics – Drug Profile Updates 31
Lewy body Dementia Therapeutics - Dormant Products 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables
Number of Products Under Development for Lewy body Dementia, H2 2012 7
Products under Development for Lewy body Dementia – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Eisai Co., Ltd., H2 2012 16
BioArctic Neuroscience AB, H2 2012 17
Varinel, Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Lewy body Dementia Therapeutics – Drug Profile Updates 31
Lewy body Dementia Therapeutics – Dormant Products 32

List of Figures
Number of Products under Development for Lewy body Dementia, H2 2012 7
Products under Development for Lewy body Dementia – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Customers who bought this item also bought

• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Lymphoma - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Alzheimer's Disease - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Myelodysplastic Syndrome - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012